Literature DB >> 20118976

Medical oncology: treatment and management of malignant gliomas.

Deric M Park, Sith Sathornsumetee, Jeremy N Rich.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20118976     DOI： 10.1038/nrclinonc.2009.221

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  10 in total

1.  AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients.

Authors:  Tracy T Batchelor; A Gregory Sorensen; Emmanuelle di Tomaso; Wei-Ting Zhang; Dan G Duda; Kenneth S Cohen; Kevin R Kozak; Daniel P Cahill; Poe-Jou Chen; Mingwang Zhu; Marek Ancukiewicz; Maciej M Mrugala; Scott Plotkin; Jan Drappatz; David N Louis; Percy Ivy; David T Scadden; Thomas Benner; Jay S Loeffler; Patrick Y Wen; Rakesh K Jain
Journal:  Cancer Cell       Date:  2007-01       Impact factor: 31.743

2.  Glioma stem cells promote radioresistance by preferential activation of the DNA damage response.

Authors:  Shideng Bao; Qiulian Wu; Roger E McLendon; Yueling Hao; Qing Shi; Anita B Hjelmeland; Mark W Dewhirst; Darell D Bigner; Jeremy N Rich
Journal:  Nature       Date:  2006-10-18       Impact factor: 49.962

3.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.

Authors:  Roger Stupp; Warren P Mason; Martin J van den Bent; Michael Weller; Barbara Fisher; Martin J B Taphoorn; Karl Belanger; Alba A Brandes; Christine Marosi; Ulrich Bogdahn; Jürgen Curschmann; Robert C Janzer; Samuel K Ludwin; Thierry Gorlia; Anouk Allgeier; Denis Lacombe; J Gregory Cairncross; Elizabeth Eisenhauer; René O Mirimanoff
Journal:  N Engl J Med       Date:  2005-03-10       Impact factor: 91.245

4.  Bevacizumab plus irinotecan in recurrent glioblastoma multiforme.

Authors:  James J Vredenburgh; Annick Desjardins; James E Herndon; Jennifer Marcello; David A Reardon; Jennifer A Quinn; Jeremy N Rich; Sith Sathornsumetee; Sridharan Gururangan; John Sampson; Melissa Wagner; Leighann Bailey; Darell D Bigner; Allan H Friedman; Henry S Friedman
Journal:  J Clin Oncol       Date:  2007-10-20       Impact factor: 44.544

5.  Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells.

Authors:  Zhizhong Li; Shideng Bao; Qiulian Wu; Hui Wang; Christine Eyler; Sith Sathornsumetee; Qing Shi; Yiting Cao; Justin Lathia; Roger E McLendon; Anita B Hjelmeland; Jeremy N Rich
Journal:  Cancer Cell       Date:  2009-06-02       Impact factor: 31.743

6.  Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis.

Authors:  Marta Pàez-Ribes; Elizabeth Allen; James Hudock; Takaaki Takeda; Hiroaki Okuyama; Francesc Viñals; Masahiro Inoue; Gabriele Bergers; Douglas Hanahan; Oriol Casanovas
Journal:  Cancer Cell       Date:  2009-03-03       Impact factor: 31.743

7.  Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan.

Authors:  Sith Sathornsumetee; Yiting Cao; Jennifer E Marcello; James E Herndon; Roger E McLendon; Annick Desjardins; Henry S Friedman; Mark W Dewhirst; James J Vredenburgh; Jeremy N Rich
Journal:  J Clin Oncol       Date:  2008-01-10       Impact factor: 44.544

8.  Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma.

Authors:  Henry S Friedman; Michael D Prados; Patrick Y Wen; Tom Mikkelsen; David Schiff; Lauren E Abrey; W K Alfred Yung; Nina Paleologos; Martin K Nicholas; Randy Jensen; James Vredenburgh; Jane Huang; Maoxia Zheng; Timothy Cloughesy
Journal:  J Clin Oncol       Date:  2009-08-31       Impact factor: 44.544

9.  Comprehensive genomic characterization defines human glioblastoma genes and core pathways.

Authors: 
Journal:  Nature       Date:  2008-09-04       Impact factor: 49.962

10.  IDH1 and IDH2 mutations in gliomas.

Authors:  Hai Yan; D Williams Parsons; Genglin Jin; Roger McLendon; B Ahmed Rasheed; Weishi Yuan; Ivan Kos; Ines Batinic-Haberle; Siân Jones; Gregory J Riggins; Henry Friedman; Allan Friedman; David Reardon; James Herndon; Kenneth W Kinzler; Victor E Velculescu; Bert Vogelstein; Darell D Bigner
Journal:  N Engl J Med       Date:  2009-02-19       Impact factor: 176.079
  10 in total
  13 in total

1.  Implications for damage recognition during Dpo4-mediated mutagenic bypass of m1G and m3C lesions.

Authors:  Olga Rechkoblit; James C Delaney; John M Essigmann; Dinshaw J Patel
Journal:  Structure       Date:  2011-06-08       Impact factor: 5.006

2.  Elevated invasive potential of glioblastoma stem cells.

Authors:  Lin Cheng; Qiulian Wu; Olga A Guryanova; Zhi Huang; Qian Huang; Jeremy N Rich; Shideng Bao
Journal:  Biochem Biophys Res Commun       Date:  2011-03-01       Impact factor: 3.575

3.  Tumor Suppressor Candidate 1 Suppresses Cell Growth and Predicts Better Survival in Glioblastoma.

Authors:  Rui Zhang; Wan Yu; Guanyu Liang; Zhanjun Jia; Zhengxin Chen; Lin Zhao; Yongsheng Yuan; Xiaobin Zhou; Daqian Li; Shuying Shen; Ning Liu; Aihua Zhang; Huibo Wang; Gang Wang
Journal:  Cell Mol Neurobiol       Date:  2016-02-20       Impact factor: 5.046

4.  Cytotoxic and Antiproliferative Effects of β-Mangostin on Rat C6 Glioma Cells Depend on Oxidative Stress Induction via PI3K/AKT/mTOR Pathway Inhibition.

Authors:  Kaiqiang Li; Lingling Wu; Yili Chen; Yuanyuan Li; Qianni Wang; Min Li; Ke Hao; Wei Zhang; Shanshan Jiang; Zhen Wang
Journal:  Drug Des Devel Ther       Date:  2020-12-01       Impact factor: 4.162

5.  MiR-218 sensitizes glioma cells to apoptosis and inhibits tumorigenicity by regulating ECOP-mediated suppression of NF-κB activity.

Authors:  Hongping Xia; Yukui Yan; Minghua Hu; Yaxian Wang; Yongsheng Wang; Yi Dai; Jianming Chen; Guangfu Di; Xiaobing Chen; Xiaochun Jiang
Journal:  Neuro Oncol       Date:  2012-12-14       Impact factor: 12.300

6.  Ionizing radiations sustain glioblastoma cell dedifferentiation to a stem-like phenotype through survivin: possible involvement in radioresistance.

Authors:  P Dahan; J Martinez Gala; C Delmas; S Monferran; L Malric; D Zentkowski; V Lubrano; C Toulas; E Cohen-Jonathan Moyal; A Lemarie
Journal:  Cell Death Dis       Date:  2014-11-27       Impact factor: 8.469

7.  Fluoxetine, an antidepressant, suppresses glioblastoma by evoking AMPAR-mediated calcium-dependent apoptosis.

Authors:  Kao-Hui Liu; Shun-Tai Yang; Yen-Kuang Lin; Jia-Wei Lin; Yi-Hsuan Lee; Jia-Yi Wang; Chaur-Jong Hu; En-Yuan Lin; Shu-Mei Chen; Chee-Kin Then; Shing-Chuan Shen
Journal:  Oncotarget       Date:  2015-03-10

8.  Disruption of NF-κB signaling by fluoxetine attenuates MGMT expression in glioma cells.

Authors:  Tao Song; Hui Li; Zhiliang Tian; Chaojiu Xu; Jingfang Liu; Yong Guo
Journal:  Onco Targets Ther       Date:  2015-08-20       Impact factor: 4.147

9.  Escitalopram oxalate induces apoptosis in U-87MG cells and autophagy in GBM8401 cells.

Authors:  Vincent Chin-Hung Chen; Yi-Hsien Hsieh; Li-Jeng Chen; Tsai-Ching Hsu; Bor-Show Tzang
Journal:  J Cell Mol Med       Date:  2017-11-03       Impact factor: 5.310

10.  Ionizing radiation induces endothelial transdifferentiation of glioblastoma stem-like cells through the Tie2 signaling pathway.

Authors:  Pauline Deshors; Christine Toulas; Florent Arnauduc; Laure Malric; Aurore Siegfried; Yvan Nicaise; Anthony Lemarié; Dorian Larrieu; Marie Tosolini; Elizabeth Cohen-Jonathan Moyal; Monique Courtade-Saidi; Solène M Evrard
Journal:  Cell Death Dis       Date:  2019-10-28       Impact factor: 8.469
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.